GLP-1 Receptor Agonists: A Comparative Mechanism Review

The incretin pharmacology landscape has moved rapidly from a single approved long-acting GLP-1 agonist class to a generation of dual and triple receptor agonists with substantially different pharmacological profiles. The compounds in current clinical use or late-stage development — semaglutide, tirzepatide, and retatrutide — share a common design strategy of fatty-acid acylation for albumin binding and once-weekly pharmacokinetics, but their receptor activities and therapeutic effects differ in ways that are increasingly relevant to clinical conversation.

This brief reviews the three compounds side-by-side: receptor selectivity, signaling pharmacology, pharmacokinetic profile, and the principal mechanistic distinctions emerging from preclinical and clinical work to date. It is not a clinical guidance document; the goal is to give the practitioner a concise reference for the molecular and pharmacological differences that shape the literature.

The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic β-cells, α-cells, gastric smooth muscle, and multiple central nervous system populations — most relevantly in the area postrema, nucleus of the solitary tract, and arcuate nucleus of the hypothalamus. Native GLP-1(7-37) and GLP-1(7-36) amide bind the receptor with high affinity but are degraded within minutes by dipeptidyl peptidase-4 (DPP-4), limiting the native peptide to a transient post-prandial signal.

Long-acting agonists overcome this limitation either by enzymatic resistance (Aib substitution at position 8) or by reversible albumin binding via fatty-acid acylation. All three compounds reviewed here use both strategies in combination.

Semaglutide is the reference compound for once-weekly GLP-1 receptor agonism. The structure is a 31-amino-acid analog of native GLP-1 with an Aib substitution at position 8 conferring DPP-4 resistance and a C18 fatty diacid linked via a γ-glutamyl-2xOEG spacer at Lys26. The acylation strategy produces a circulating half-life of approximately 165 hours, supporting once-weekly dosing.

Pharmacologically, semaglutide is a full agonist at the GLP-1 receptor with no meaningful activity at other incretin receptors. Downstream effects include glucose-dependent insulinotropic activity, glucagon suppression, slowed gastric emptying, and engagement of central GLP-1R populations that suppress appetite and food intake. The cardiovascular and renal outcome data developed across the SUSTAIN and SELECT programs has shaped the modern clinical conversation around metabolic-disease pharmacotherapy.

For comparative purposes, semaglutide is the cleanest reference point in the modern incretin literature — a selective, well-characterized GLP-1 agonist against which dual and triple agonists are evaluated.

Tirzepatide is a 39-amino-acid peptide built on the native GIP backbone with substitutions that introduce GLP-1 receptor activity. The C20 fatty diacid at Lys20 provides a circulating half-life of approximately five days. The result is a compound with substantial agonism at both the GIP and GLP-1 receptors — historically termed a "twincretin" — and a notable signaling bias at GLP-1R, where cAMP signaling is preserved and β-arrestin recruitment is reduced relative to native GLP-1.

The GIP arm is the principal pharmacological distinction. GIP receptor signaling potentiates insulin response in the post-prandial state and is hypothesized to modulate adipocyte function, lipid metabolism, and energy expenditure — though the precise contribution of GIP agonism to weight loss in humans remains an active research question. The SURPASS and SURMOUNT programs have produced the largest direct comparator dataset between a dual agonist and a selective GLP-1 agonist, with tirzepatide producing larger weight reductions than semaglutide at matched doses.

Reduced β-arrestin recruitment at GLP-1R is the leading mechanistic hypothesis for the comparatively lower receptor desensitization observed in preclinical models, and may also contribute to the gastrointestinal tolerability profile reported clinically.

Retatrutide (LY3437943) extends the multi-receptor strategy to the glucagon receptor. The 39-amino-acid peptide is a substantial agonist at the GLP-1, GIP, and glucagon receptors, with the glucagon arm providing the principal mechanistic distinction from tirzepatide.

Hepatic glucagon receptor activation increases energy expenditure, promotes hepatic fatty acid oxidation, and reduces hepatic steatosis in preclinical models. The combination of glucagon-driven energy expenditure with incretin-driven appetite suppression is the hypothesized basis for the larger weight-loss magnitudes reported in Phase 2 trials. Published data report mean weight reductions of approximately 24% at 48 weeks at the highest dose — the largest effects observed in any pharmacological metabolic program to date.

The glucagon arm also introduces a distinct safety conversation. Glucagon receptor activation transiently elevates hepatic glucose output, which is countered in vivo by the incretin arms but warrants ongoing monitoring in clinical development. The receptor balance — near-equipotent GLP-1 and glucagon activity with somewhat lower GIP potency in published reports — has been deliberately engineered to optimize this trade-off.

All three compounds use fatty-acid acylation for albumin binding and once-weekly dosing. Semaglutide half-life is approximately seven days; tirzepatide approximately five days; retatrutide approximately six days. Time to steady-state is therefore in the four-to-six-week range across the class, and the practical implication is that mechanism comparisons require multi-week protocols rather than acute pharmacodynamic readouts.

Route of administration is subcutaneous for all three. Oral semaglutide (Rybelsus) uses an absorption-enhancer co-formulation to achieve oral bioavailability, but the dual and triple agonists are subcutaneous-only at this time.

The core mechanistic question across the class is the relative contribution of each receptor arm to the observed weight-loss and metabolic effects. The selective GLP-1 agonism of semaglutide is the cleanest reference, and the incremental effects observed with tirzepatide and retatrutide can be attributed primarily to the GIP and glucagon arms respectively — with the caveat that receptor potency at each target is engineered differently across the compounds and direct attribution is not straightforward.

For practitioners reading the literature, the most useful framing is that semaglutide establishes the baseline of what selective GLP-1 agonism can achieve; tirzepatide demonstrates the incremental contribution of GIP receptor activation in combination; and retatrutide demonstrates the further incremental contribution of glucagon receptor activation. The class as a whole continues to evolve, and additional triple and quadruple agonists are in earlier development.

The three compounds reviewed here are best understood as a progression within a single pharmacological family rather than competing alternatives. Each adds a receptor arm to the previous and produces incrementally larger metabolic effects in clinical trials, with corresponding differences in mechanism and safety profile.

Documentation for any specific compound — including a lot-specific Certificate of Analysis, the full peer-reviewed reference list, and the comparison table for related compounds — is available through the Park Ave reference library.